<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Paret C</submitter><funding>Stiftung Kinderkrebsforschung Mainz</funding><funding>HI-TRON Mainz</funding><pagination>8431</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12428964</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>26(17)</volume><pubmed_abstract>High-risk (HR) neuroblastoma (NBL) patients often receive standardized treatment despite wide variations in clinical outcomes, underscoring the need for improved stratification tools. A distinguishing feature of NBL is the patient-specific expression of gangliosides (GGs), particularly GD2, which may serve as biomarkers. We analyzed GG profiles in 18 patient-derived tumors and 11 NBL cell lines using thin-layer chromatography and mass spectrometry. Expression of 0-, a-, and b-series GGs was examined and correlated with clinical risk, outcome, and gene expression data. Low-risk (LR) tumors expressed higher levels of complex b-series GGs. In HR tumors, five GG profiles (A-E) were identified. Profile A featured complex b-series GGs; B showed GD2 dominance; C showed synthesis arrest at GM3 or </pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.</pubmed_title><pmcid>PMC12428964</pmcid><funding_grant_id>SKFM_01_2022</funding_grant_id><funding_grant_id>HITR-2021-14</funding_grant_id><pubmed_authors>Wingerter A</pubmed_authors><pubmed_authors>Brignole C</pubmed_authors><pubmed_authors>Ustjanzew A</pubmed_authors><pubmed_authors>Seidmann L</pubmed_authors><pubmed_authors>Schwickerath P</pubmed_authors><pubmed_authors>Sandhoff R</pubmed_authors><pubmed_authors>Faber J</pubmed_authors><pubmed_authors>Ludwig J</pubmed_authors><pubmed_authors>El Malki K</pubmed_authors><pubmed_authors>Pastorino F</pubmed_authors><pubmed_authors>Wagner S</pubmed_authors><pubmed_authors>Sathyamurthy S</pubmed_authors><pubmed_authors>Roth W</pubmed_authors><pubmed_authors>Paret C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.</name><description>High-risk (HR) neuroblastoma (NBL) patients often receive standardized treatment despite wide variations in clinical outcomes, underscoring the need for improved stratification tools. A distinguishing feature of NBL is the patient-specific expression of gangliosides (GGs), particularly GD2, which may serve as biomarkers. We analyzed GG profiles in 18 patient-derived tumors and 11 NBL cell lines using thin-layer chromatography and mass spectrometry. Expression of 0-, a-, and b-series GGs was examined and correlated with clinical risk, outcome, and gene expression data. Low-risk (LR) tumors expressed higher levels of complex b-series GGs. In HR tumors, five GG profiles (A-E) were identified. Profile A featured complex b-series GGs; B showed GD2 dominance; C showed synthesis arrest at GM3 or </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-04-08T19:14:38.609Z</modification><creation>2026-04-08T12:07:36.567Z</creation></dates><accession>S-EPMC12428964</accession><cross_references><pubmed>40943355</pubmed><doi>10.3390/ijms26178431</doi></cross_references></HashMap>